Exome sequencing provides a cost-effective alternative to whole genome sequencing as it targets only the protein coding region of the human genome responsible for a majority of known disease related variants. Whether you are conducting studies in rare Mendelian disorders, complex disease, cancer research, or human population studies, Novogene’s comprehensive human whole exome sequencing service provides a high-quality, affordable and convenient solution.
Novogene’s bioinformatics analysis includes data QC, mapping with reference genome, SNP/InDel, somatic SNP/InDel calling, statistics and annotation. Novogene utilizes internationally recognized software in bioinformatics analysis, e.g. BWA, SAMtools, GATK, etc.
In particular, Novogene bioinformatics pipeline includes annotation with the exome aggregation consortium (ExAC). ExAC dataset spans 60,706 unrelated individuals sequenced as part of various disease-specific and population genetic studies. This population scale database greatly facilitates research of disease pathogenesis.
The Novogene Advantage
- Unsurpassed data quality: We guarantee a Q30 score ≥80%, exceeding Illumina’s official guarantee of ≥75%. See our data example.
- State-of-the-art exome capture: Agilent SureSelect Human All Exome V6 (58 M) / V5 (50 M) are used.
- Accurate variant calling with longer read length up to 150 bp.
- Extraordinary informatics expertise: Novogene uses its cutting-edge bioinformatics pipeline and internationally recognized best-in-class software to provide customers with “publication-ready data”.
- Agilent SureSelect Human All Exon V5/V6 Kit
- 350 bp insert DNA library
- HiSeq platform, paired-end 150 bp
Data Quality Guarantee
- We guarantee that ≥ 80% of bases have a sequencing quality score ≥ Q30, which exceeds Illumina’s official guarantee of ≥ 75%.
- Input DNA:
- For fresh sample: ≥ 1.0 μg (a minimum of 200 ng can be accepted with risk)
- For FFPE sample: ≥ 1.5 μg
- DNA concentration: ≥ 20 ng/μl
- DNA Volume: ≥ 10 μl
- OD260/280 = 1.8 - 2.0 without degradation or RNA contamination
- 22 working days after verification of sample quality (without data analysis)
- Additional 5 working days for data analysis
Recommended Sequencing Depth
- For Mendelian disorder/rare disease: effective sequencing depth above 50×
- For tumor sample: effective sequencing depth above 100×
Novogene provides the highest quality NGS services. We guarantee that over 80% of bases will have a sequencing quality score ≥ Q30. In standard practice, Novogene achieves an average Q30 of 91.07%, exceeding Illumina’s official guarantee of 75%.
Additionally, an average of 98.3% of our raw sequencing data passes the quality control standards for effective clean data.
The following table includes actual Novogene data from human exome sequencing projects, and demonstrates the quality of our sequencing. Alignment of the results to the reference genome (UCSC hg19) showed an average mapping ratio of 99.71%.
Table. Representative whole exome sequencing data from Novogene
1 Original sequencing data (in gigabases).
2 Percentage of clean reads from all raw reads.
3 Average error rate of all bases in read1 and read2.
4 Percentage of reads with an average quality greater than Q20.
5 Percentage of reads with an average quality greater than Q30.
6 Percentage of G and C bases from total bases.
7 Percentage of total reads that mapped to the reference genome.
8 Average sequencing depth (times coverage) per reference genome target region.
9 Percentage of target region covered by sequencing.
10 Percentage of bases in target region with a sequencing depth ≥ 4x.
11 Percentage of bases in target region with a sequencing depth ≥ 10x.
12 Percentage of bases in target region with a sequencing depth ≥ 20x.
Project ExampleThe following study utilized Novogene's expert exome sequencing service.
Identification of a Novel Mutation in the Titin Gene in a Chinese Family with Limb-Girdle Muscular Dystrophy 2J
Molecular Neurobiology (2015):1-6.
This study explored the genetic basis for an inherited myopathy, limb-girdle muscular dystrophy 2J (LGMD2J), in a multigenerational Chinese family. An exome library from a family member with LGMD2J was prepared and sequenced at Novogene, and bioinformatics analysis revealed a novel homozygous point mutation in the titin gene, which is known to be associated with LGMD2J. Further analyses revealed that the homozygous variant was present in family members with this form of muscular dystrophy, but that individuals who did not exhibit the condition were either heterozygous or did not have the mutation. These findings will contribute to the understanding of the disease and to improve genetic testing.
Figure. Screening for the novel titin gene mutation associated with LGMD2J. a) Relationships and presence/absence of LGMD2J in the family under study. N and M indicate, respectively, the normal and mutated titin gene. Panels b-d, partial sequence of the titin gene from different individuals showing the region of the novel mutation. b) no mutation, c) heterozygous variant, d) homozygous variant.
Examples of Publications Using Novogene’s Services
|Identification of a Novel Mutation in the Titin Gene in a Chinese Family with Limb-Girdle Muscular Dystrophy 2J|
|Plos One, 2015, 10.||Identification of a Novel MYO15A Mutation in a Chinese Family with Autosomal Recessive Nonsyndromic Hearing Loss|